Company

OKKLO Life Sciences

The company was founded in December 2011 by a team of life-sciences experts previously involved in the development and approval of sugammadex (Bridion™), the first modified cyclodextrin (CD) marketed as a drug product.

What we offer

Unique expertise in development of cyclodextrin-based therapeutics
Track-record of successful submissions and approvals in EU, US and Japan
SME partner in collaborative (pre-competitive) projects
Partnering and licensing opportunities

Okklo Life Sciences

Transistorweg 5 (Building M)

6534 AT Nijmegen

The Netherlands

+31 6 1048 9150

info@okklo.com

Website

More companies in this area

Pleco Therapeutics

Our current pre-clinical development programs focus on the development of treatments for Acute Myeloid Leukaemia (AML), a relatively rare blood cancer, and Small-Cell Lung Cancer (SCLC), an aggressive subtype of lung cancer.

GCP-Service International

GCP-Service International is a mid-size contract research organization (CRO), with branches across Germany, Netherlands, Poland and Czech Republic.

DFE Pharma

DFE Pharma develops, produces and supplies excipients for use in oral solid dose and dry powder inhalation,

Vaxxinova

Vaxxinova develops, produces and markets a wide range of innovative vaccines and diagnostic services to protect livestock and fish against diseases.

TropIQ

TropIQ Health Sciences offers laboratory screening services for the discovery and development of drugs against malaria.

Protinhi Therapeutics

Protinhi Therapeutics is an early stage biotech company, developing novel drugs against diseases with a high unmet medical need using proprietary technology and compounds that target diseases via Protease Inhibition. The focus of Protinhi is on upcoming viral threats and particularly on Dengue and Zika.

Settle at Novio Tech Campus!

Connect with Novio Tech Campus!